<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336538">
  <stage>Registered</stage>
  <submitdate>26/02/2011</submitdate>
  <approvaldate>7/03/2011</approvaldate>
  <actrnumber>ACTRN12611000246987</actrnumber>
  <trial_identification>
    <studytitle>The Effect of Granulocyte Colony Stimulating Factor (GCSF) on Immune Response to Hepatitis B Vaccine in End-Stage Renal Disease (ESRD) Patients Undergoing Hemodialysis</studytitle>
    <scientifictitle>The titer of Anti HBS Ab in hemodialysis patients receiving double dose HBV vaccine and simultaneous granulocyte-colony stimulating factor (G-CSF) is higher compared to hemodialysis patients receiving only double dose HBV vaccine</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>N/A</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Immunity against hepatitis B virus</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intramuscular injection of double dose of HBV vaccine (40 micro gr) and simultaneous injection of Granolocyte monocyte colony stimulating factor (GM-CSF) (300 micro gr).
3 doses of HBV vaccine at months 0,1 and 4 will be injected. GM-CSF will be administered after each injection of HBV vaccine.</interventions>
    <comparator>Intramuscular injection of double dose of HBV vaccine without GM-CSF</comparator>
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>antibody against hepatitis B surface antigen (anti-HBS antibody) with a titer of 10IU/L or more after blood analysis,
This was measured by blood sample analysis.
The titer of anti HBS antibody in blood samples will be examined</outcome>
      <timepoint>1 month after first dose of vaccine; and again 1 month after the last dose of vaccine ((the end of 5th month )</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>None</outcome>
      <timepoint>None</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>End stage renal disease (ESRD) patients on hemodialysis</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Previous history of viral hepatitis (HBS POSITIVE OR anti HBC Ab positive

2. HIV and HCV positive patients

3. Those patients who has history of vaccination

4. Patients with chronic liver disease

5. Patients with congestive heart failure (class III and IV)

6. Patients with chronic lung disease

7. Patients with hypersensitivity to GM-CSF</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>1/04/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Iran, Islamic Republic Of</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Kamran Bagheri Lankarani</primarysponsorname>
    <primarysponsoraddress>Health policy research center,5th floor, Shiraz medical school, Zand Ave, Shiraz, Fars province, Iran.
P.C: 71345-1877</primarysponsoraddress>
    <primarysponsorcountry>Iran, Islamic Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Shiraz University of medical science-</fundingname>
      <fundingaddress>7th floor, Deputy of research and technology, Shiraz University of medical sciences, Zand Ave, Shiraz, Fars province, Iran,
P.C:71345-1845</fundingaddress>
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>Shiraz University of medical science-</sponsorname>
      <sponsoraddress>7th floor, Deputy of research and technology, Shiraz University of medical sciences, Zand Ave, Shiraz, Fars province, Iran,
P.C:71345-1845</sponsoraddress>
      <sponsorcountry>Iran, Islamic Republic Of</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Adminstration of GM-CSM along with vaccination against HBV may increase immunity and higher titers of antibody</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Local ethical committe of Shiraz University of medical sciences</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Kamran B Lankarani</name>
      <address>Health policy research center, 5th floor, Shiraz University of medical science, Zand Ave, Shiraz, Fars, Iran.
P.C: 71345-1877</address>
      <phone>0098 711 230 9615</phone>
      <fax />
      <email>lankaran@sums.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ahad Eshraghian</name>
      <address>Internal medicine department, Namazi Hospital, Shiraz, Fars, Iran 
P.C 71345-1744

Tel: 00989177311442</address>
      <phone>00989177311442</phone>
      <fax />
      <email>eshraghiana@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>